Table 5.
Prediction of CDR sum of boxes at baseline, using pNfL, Imaging Biomarkers, and APOE genotype
| Variable | Models with one biomarker | Model with Imaging Biomarkers | Model with all Biomarkers | ||||||
| df | Type III | F | df | Type III | F | df | Type III | F | |
| Mean | Mean | Mean | |||||||
| Square | Square | Square | |||||||
| Amyloid Status (A + versus A-) | 1,225 | 152.8 | 32.0*** | 1,224 | 97.2 | 22.5*** | 1,223 | 74.8 | 18.7*** |
| Hippocampal Atrophy (HP+versus Hp-) | 1,225 | 164.0 | 34.7*** | 1,224 | 108.4 | 25.2*** | 1,223 | 84.5 | 21.1*** |
| Plasma NfL | 1,224 | 138.2 | 28.5*** | 1,223 | 42.9 | 18.5*** | |||
| Age | 1,224 | 0.0 | 0.0 | 1,223 | 11.6 | 2.9 | |||
| APOE (# of ɛ4 alleles) | 1,224 | 7.1 | 1.6 | 1,223 | 9.1 | 2.3 | |||
| Model R2 | 14.5 (pNfL) | 24.1 | 29.9 | ||||||
| 16.5 (Hippocampal atrophy) | |||||||||
| 15.6 (Amyloid status) | |||||||||
All models include age and APOE as covariates. Only subjects will all imaging biomarkers are included in these models. *p < 0.05; **p < 0.01; **p < 0.001; A + versus A-: elevated versus not elevated amyloid; Hp + versus Hp-: positive versus negative for hippocampal atrophy.